Olympiad Research LP Makes New Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Olympiad Research LP acquired a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 31,530 shares of the company’s stock, valued at approximately $147,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Point72 Asset Management L.P. purchased a new position in GoodRx during the third quarter valued at $11,295,000. Rubric Capital Management LP boosted its holdings in shares of GoodRx by 25.2% during the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after purchasing an additional 943,226 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of GoodRx during the third quarter valued at about $5,675,000. Pier Capital LLC bought a new stake in shares of GoodRx in the third quarter worth about $3,259,000. Finally, Raymond James & Associates lifted its position in shares of GoodRx by 212.6% in the third quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock worth $2,734,000 after buying an additional 267,951 shares in the last quarter. Institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GDRX shares. Barclays cut their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Morgan Stanley reduced their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. KeyCorp lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Mizuho assumed coverage on shares of GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Finally, Citigroup lowered their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a report on Friday, January 10th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.38.

GoodRx Trading Down 1.0 %

GDRX opened at $4.81 on Monday. The stock’s 50 day moving average price is $4.67 and its 200-day moving average price is $5.80. GoodRx Holdings, Inc. has a one year low of $4.09 and a one year high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -160.33, a P/E/G ratio of 2.46 and a beta of 1.28.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.